
Biogen BIIB
€ 169.02
0.26%
Quartalsbericht 2026-Q1
hinzugefügt 29.04.2026
Biogen Langfristiger Schuldenstrom 2011-2026 | BIIB
Langfristiger Schuldenstrom Jährlich Biogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80.4 M | 86.4 M | 90.3 M | 97.2 M | 89.1 M | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 97.2 M | 80.4 M | 88.7 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
102 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
1.83 M | $ 1.61 | -2.73 % | $ 189 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Celldex Therapeutics
CLDX
|
1.55 M | $ 31.72 | 0.05 % | $ 2.11 B | ||
|
BioNTech SE
BNTX
|
45 M | $ 96.94 | 3.75 % | $ 23.4 B | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 55.72 | -1.17 % | $ 5.01 B | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M | ||
|
Compugen Ltd.
CGEN
|
521 K | $ 2.69 | -3.24 % | $ 251 M | ||
|
Abcam plc
ABCM
|
8.5 M | - | - | $ 4.9 B | ||
|
Galera Therapeutics
GRTX
|
133 K | - | -32.59 % | $ 7.61 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
235 K | $ 0.82 | 6.92 % | $ 37.5 M | ||
|
Affimed N.V.
AFMD
|
539 K | - | -34.95 % | $ 21.5 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.14 | 0.16 % | $ 653 M | ||
|
Eton Pharmaceuticals
ETON
|
65 K | $ 30.72 | -3.58 % | $ 827 M | ||
|
Forte Biosciences
FBRX
|
416 K | $ 19.3 | -7.08 % | $ 250 M | ||
|
Celyad Oncology SA
CYAD
|
137 K | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | ||
|
Galectin Therapeutics
GALT
|
22 K | $ 2.54 | -1.17 % | $ 162 M | ||
|
Generation Bio Co.
GBIO
|
13 M | - | - | $ 344 M | ||
|
IMV
IMV
|
320 K | - | - | $ 13.1 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 7.93 | -0.63 % | $ 5.39 B | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
2.66 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
17.5 M | - | - | $ 3.37 B | ||
|
Heron Therapeutics
HRTX
|
3.04 M | $ 0.87 | -2.33 % | $ 145 M | ||
|
ImmuCell Corporation
ICCC
|
85.5 K | $ 10.11 | 2.12 % | $ 91.3 M | ||
|
Anika Therapeutics
ANIK
|
2.05 M | $ 14.71 | -1.28 % | $ 211 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
56 K | $ 3.38 | -1.46 % | $ 5.56 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M |